Fundz

Tenvie Therapeutics raised $200 million to develop small molecules for treating neurological disorders.

PRIVATEJan 08, 2025

Amount Raised

$200 Million

Round Type

Funding Round

South San FranciscoBiotechnologyHealth CareTherapeutics

Investors

Mubadala CapitalF Prime CapitalARCH Venture Partners

Description

Tenvie Therapeutics secured $200 million in its debut financing round, making it the largest raise among the recent batch of biotech funding. This financing aims to support the development of their innovative treatments for neurological disorders.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Tenvie Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Ceretas raised $1M (Seed) on February 21, 2025.
  • Humane Genomics raised an undisclosed amount (Seed) on February 21, 2025.
  • Reverb Therapeutics raised $12M (Seed) on February 19, 2025.
  • MAIA Biotechnology raised $4.1M (Seed) on February 18, 2025.
  • Bambusa Therapeutics raised $90M (Series A) on February 14, 2025.
  • StemSight raised $2.4M (Seed) on February 14, 2025.

Who to call at Tenvie Therapeutics, and when

A new round usually means Tenvie Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Tenvie Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Tenvie Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Tenvie Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Tenvie Therapeutics

Location

South San Francisco, California, United States

About

Tenvie is a biotechnology company committed to engineering small molecules that transform the treatment of neurological diseases. The company’s foundation is purpose-built with a diverse portfolio of small molecules and a proven team of CNS drug developers to rapidly deliver multiple clinical assets. Tenvie is advancing a pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases. Its portfolio of wholly owned, highly brain-penetrant, and precision-designed peripherally restricted small molecules address three key drivers of disease: resolving inflammation, rescuing metabolic dysfunction, and restoring lysosomal function. The company’s most advanced programs target NLRP3 and SARM1, with additional programs in preclinical development.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Tenvie Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Tenvie Therapeutics's next move

See what Strategic adds

Tenvie Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.